- Home
- PTMN vs AGEN Comparison
PTMN vs AGEN Comparison
Compare PTMN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTMN
- AGEN
- Stock Information
- Founded
- PTMN 2006
- AGEN 1994
- Country
- PTMN United States
- AGEN United States
- Employees
- PTMN N/A
- AGEN N/A
- Industry
- PTMN Finance: Consumer Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PTMN Finance
- AGEN Health Care
- Exchange
- PTMN Nasdaq
- AGEN Nasdaq
- Market Cap
- PTMN 107.9M
- AGEN 87.7M
- IPO Year
- PTMN N/A
- AGEN 2000
- Fundamental
- Price
- PTMN $12.60
- AGEN $5.29
- Analyst Decision
- PTMN Hold
- AGEN Buy
- Analyst Count
- PTMN 1
- AGEN 4
- Target Price
- PTMN $14.00
- AGEN $13.00
- AVG Volume (30 Days)
- PTMN 39.0K
- AGEN 1.7M
- Earning Date
- PTMN 08-07-2025
- AGEN 08-07-2025
- Dividend Yield
- PTMN 15.61%
- AGEN N/A
- EPS Growth
- PTMN N/A
- AGEN N/A
- EPS
- PTMN N/A
- AGEN N/A
- Revenue
- PTMN $58,024,000.00
- AGEN $99,524,000.00
- Revenue This Year
- PTMN N/A
- AGEN $12.69
- Revenue Next Year
- PTMN $12.20
- AGEN N/A
- P/E Ratio
- PTMN N/A
- AGEN N/A
- Revenue Growth
- PTMN N/A
- AGEN N/A
- 52 Week Low
- PTMN $11.48
- AGEN $1.38
- 52 Week High
- PTMN $19.95
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- PTMN 58.87
- AGEN 55.11
- Support Level
- PTMN $12.45
- AGEN $4.34
- Resistance Level
- PTMN $12.74
- AGEN $5.05
- Average True Range (ATR)
- PTMN 0.25
- AGEN 0.38
- MACD
- PTMN 0.08
- AGEN -0.09
- Stochastic Oscillator
- PTMN 88.19
- AGEN 60.80
About PTMN Portman Ridge Finance Corporation
Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).